Investigational New Drugs: Fda Has Taken Steps To Improve The Expanded Access Program But Should Further Clarify How Adverse Events Data Are Used

Publisher: United States. Government Accountability Office
Coverage: July 11, 2017

Volumes:

GAO-17-564 (2017-07-11)